8-K Announcements
6Material company update
Jun 3, 2026·SEC
Material company update
Mar 31, 2026·SEC
Material company update
Mar 9, 2026·SEC
BriaCell Therapeutics Corp.(BCTX)Earnings, Financials & Key Ratios
BCTX•NASDAQ
Price updated Jun 19, 2026
AboutBriaCell Therapeutics Corp., an immuno-oncology biotechnology company, engages in developing immunotherapies for the treatment of cancer. Its lead candidate is Bria-IMT that is in Phase I/IIa clinical trial in a combination study with immune checkpoint inhibitors for the treatment of breast cancer. The company also has a cooperative research and development agreement with the National Cancer Institute for developing Bria-OTS, a personalized immunotherapy for advanced breast cancer; and BriaDx, a diagnostic test. BriaCell Therapeutics Corp. is headquartered in West Vancouver, Canada.Show more
- Revenue$0
- EBITDA-$38M-13.0%
- Net Income-$36M-661.4%
- EPS (Diluted)-62.60-45.5%
- ROE-363.02%
BCTX Key Insights
BriaCell Therapeutics Corp. (BCTX) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Trading at only 0.2x book value
✗Weaknesses
- ✗Profits declining 49.2% over 5 years
- ✗Weak Piotroski F-Score: 1/9
- ✗Weak momentum: RS Rating 6 (bottom 6%)
- ✗Shares diluted 71.7% in last year
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when BCTX posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
BCTX Price & Volume
BriaCell Therapeutics Corp. (BCTX) stock price & volume — 10-year historical chart
Loading chart...
BCTX Growth Metrics
BriaCell Therapeutics Corp. (BCTX) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-34.78%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM59.63%
Return on Capital
10 Years-754.28%
5 Years-136.04%
3 Years-207.81%
Last Year-341.6%
BCTX Recent Earnings
BriaCell Therapeutics Corp. (BCTX) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 4/12 qtrs (50%)
Q3 2026Latest
Jun 9, 2026Metric
Actual
Est
EPS
$0.99
—
Rev
—
—
Q2 2026
Mar 10, 2026Metric
Actual
Est
EPS
$2.58+46.7%
$4.84
Rev
—
—
Q4 2025
Dec 11, 2025Metric
Actual
Est
EPS
$4.35
—
Rev
—
—
Q4 2025
Oct 27, 2025Metric
Actual
Est
EPS
$10.49+13.4%
$12.11
Rev
—
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q3 2026Latest | Jun 9, 2026 | $0.99 | — |
| Q2 2026 | Mar 10, 2026 | $2.58vs $4.84+46.7% | — |
| Q4 2025 | Dec 11, 2025 | $4.35 | — |
| Q4 2025 | Oct 27, 2025 | $10.49vs $12.11+13.4% | — |
Based on last 12 quarters of dataView full earnings history →
BCTX Peer Comparison
BriaCell Therapeutics Corp. (BCTX) competitors in Oncology Therapeutics Developers — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 NKTR | 1.19B | 60.98 | -6.27 | -43.89% | -284.18% | -87% | 1.66 | |
 IMVT | 7.26B | 35.34 | -12.76 | -68.16% | 0.00 | |||
 ADCT | 138.64M | 1.09 | -0.97 | 14.85% | -173.02% | |||
 CRIS | 81.52M | 0.42 | -0.73 | -13.43% | -299.66% | -138.81% | 0.30 | |
 HALO | 8.13B | 68.55 | 26.78 | 37.55% | 23.13% | 126.27% | 43.89 | |
 IOVA | 1.4B | 3.91 | -3.59 | 60.6% | -123.9% | -50.17% | 0.07 | |
 NUVL | 9.08B | 123.43 | -21.10 | -42.78% | ||||
 FATE | 243.61M | 2.09 | -1.82 | -51.24% | -20.57% | -58.89% | 0.38 |
Compare BCTX vs Peers
BriaCell Therapeutics Corp. (BCTX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
BCTX Income Statement
BriaCell Therapeutics Corp. (BCTX) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Jul'17 | Jul'18 | Jul'19 | Jul'20 | Jul'21 | Jul'22 | Jul'23 | Jul'24 | Jul'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Revenue Growth % | - | - | - | - | - | - | - | - | - | - |
Cost of Goods Sold | 290 | 16.88K | 18.83K | 18.73K | 15.58K | 15.14K | 15.53K | 82.57K | 147.89K | 89.96K |
COGS % of Revenue | - | - | - | - | - | - | - | - | - | - |
Gross Profit | -289▲ 0% | -16.88K▼ 5739.8% | -18.83K▼ 11.6% | -18.73K▲ 0.5% | -15.58K▲ 16.8% | -15.14K▲ 2.8% | -15.53K▼ 2.6% | -82.57K▼ 431.7% | -147.89K▼ 79.1% | -89.96K▲ 0% |
Gross Margin % | - | - | - | - | - | - | - | - | - | - |
Gross Profit Growth % | 83.97% | -5739.79% | -11.59% | 0.52% | 16.84% | 2.83% | -2.58% | -431.73% | -79.1% | - |
Operating Expenses | 3.21M | 4.96M | 6.23M | 4.82M | 8.72M | 19.61M | 31.08M | 33.34M | 37.58M | 38.58M |
OpEx % of Revenue | - | - | - | - | - | - | - | - | - | - |
Selling, General & Admin | 1.09M | 1.85M | 1.29M | 1.84M | 6.19M | 9.32M | 10.6M | 6.15M | 8.08M | 7.9M |
SG&A % of Revenue | - | - | - | - | - | - | - | - | - | - |
Research & Development | 2.12M | 3.11M | 4.94M | 2.98M | 2.53M | 10.29M | 20.48M | 27.19M | 29.5M | 33.31M |
R&D % of Revenue | - | - | - | - | - | - | - | - | - | - |
Other Operating Expenses | 0 | 0 | 0 | 0 | -3.17K | 0 | 0 | 0 | 0 | -1000K |
Operating Income | -3.21M▲ 0% | -4.97M▼ 54.6% | -6.25M▼ 25.8% | -5.28M▲ 15.6% | -8.72M▼ 65.2% | -19.61M▼ 125.0% | -31.08M▼ 58.5% | -33.34M▼ 7.3% | -37.73M▼ 13.2% | -31.02M▲ 0% |
Operating Margin % | - | - | - | - | - | - | - | - | - | - |
Operating Income Growth % | -46.55% | -54.65% | -25.76% | 15.61% | -65.17% | -124.98% | -58.51% | -7.28% | -13.17% | - |
EBITDA | -3.21M | -4.96M | -6.23M | -5.26M | -8.7M | -19.59M | -31.06M | -33.26M | -37.58M | -30.92M |
EBITDA Margin % | - | - | - | - | - | - | - | - | - | - |
EBITDA Growth % | -46.65% | -54.14% | -25.8% | 15.66% | -65.4% | -125.25% | -58.57% | -7.08% | -13.01% | 9.78% |
D&A (Non-Cash Add-back) | 290 | 16.88K | 18.83K | 18.73K | 19.07K | 19.59K | 20.39K | 83.93K | 147.89K | 100.93K |
EBIT | -3.22M | -5.39M | -5.79M | -4.84M | -17.17M | -34.42M | -31.08M | -4.93M | -37.73M | -31.02M |
Net Interest Income | 6.42K | -4.37K | -19.41K | -36.2K | -96.2K | 172.61K | 1.2M | 283.61K | 115.09K | 240.48K |
Interest Income | 6.42K | 15.97K | 12.06K | 0 | 4.02K | 173.86K | 1.2M | 283.61K | 166.38K | 240.48K |
Interest Expense | 0 | 20.34K | 31.47K | 36.2K | 100.22K | 1.24K | 0 | 0 | 51.29K | 0 |
Other Income/Expense | -2.48K | -435.76K | 434.77K | -113.98K | -8.55M | -14.81M | 3.97M | 28.41M | 899.68K | 834.34K |
Pretax Income | -3.22M▲ 0% | -5.41M▼ 68.1% | -5.82M▼ 7.6% | -5.39M▲ 7.3% | -17.27M▼ 220.3% | -34.42M▼ 99.3% | -27.11M▲ 21.2% | -4.93M▲ 81.8% | -36.83M▼ 646.6% | -37.35M▲ 0% |
Pretax Margin % | - | - | - | - | - | - | - | - | - | - |
Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Net Income | -3.22M▲ 0% | -5.41M▼ 68.1% | -5.82M▼ 7.6% | -4.94M▲ 15.0% | -17.27M▼ 249.3% | -34.42M▼ 99.3% | -27.11M▲ 21.2% | -4.79M▲ 82.3% | -36.49M▼ 661.4% | -37.06M▲ 0% |
Net Margin % | - | - | - | - | - | - | - | - | - | - |
Net Income Growth % | -44.17% | -68.07% | -7.58% | 15.04% | -249.34% | -99.34% | 21.23% | 82.32% | -661.35% | -34.78% |
Net Income (Continuing) | -3.22M | -5.41M | -5.82M | -4.94M | -17.27M | -34.42M | -27.11M | -4.93M | -36.83M | -37.35M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -419.97K | -751.79K | -649.1K |
EPS (Diluted) | -1348.63▲ 0% | -1798.34▼ 33.3% | -1505.30▲ 16.3% | -5.64▲ 99.6% | -13.50▼ 139.4% | -259.50▼ 1822.2% | -195.00▲ 24.9% | -43.01▲ 77.9% | -62.60▼ 45.5% | -5.11▲ 0% |
EPS Growth % | 0.86% | -33.35% | 16.3% | 99.63% | -139.36% | -1822.22% | 24.86% | 77.94% | -45.55% | 59.63% |
EPS (Basic) | -1348.63 | -1798.34 | -1505.30 | -5.64 | -13.50 | -257.58 | -192.55 | -43.01 | -62.60 | - |
Diluted Shares Outstanding | 22.65K | 28.52K | 38.64K | 47.59K | 301.31K | 1.03M | 1.04M | 1.1M | 1.88M | 7.25M |
Basic Shares Outstanding | 22.65K | 28.52K | 38.64K | 47.59K | 301.31K | 1.03M | 1.04M | 1.1M | 1.88M | 7.25M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
BCTX Balance Sheet
BriaCell Therapeutics Corp. (BCTX) balance sheet — assets, liabilities & shareholders' equity
| Metric | Jul'17 | Jul'18 | Jul'19 | Jul'20 | Jul'21 | Jul'22 | Jul'23 | Jul'24 | Jul'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 1.63M | 1.88M | 168.53K | 261.46K | 72.23M | 54.31M | 35.99M | 5.07M | 27.4M | 25.39M |
Cash & Short-Term Investments | 1.62M | 1.75M | 157.03K | 21.25K | 71.57M | 52.63M | 28.38M | 1.2M | 24.56M | 22.8M |
Cash Only | 1.01M | 720.26K | 157.03K | 21.25K | 71.57M | 52.63M | 28.38M | 1.2M | 14.43M | 6.88M |
Short-Term Investments | 601.76K | 1.03M | 0 | 0 | 0 | 0 | 0 | 0 | 10.14M | 15.92M |
Accounts Receivable | 5.6K | 14.56K | 2.82K | 22.52K | 15.71K | 30.91K | 958.56K | 1.9M | 776.54K | 0 |
Days Sales Outstanding | - | - | - | - | - | - | - | - | - | - |
Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Days Inventory Outstanding | - | - | - | - | - | - | - | - | - | - |
Other Current Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2.59M |
Total Non-Current Assets | 1.91K | 407.5K | 276.12K | 260.87K | 306.96K | 295.41K | 287.23K | 3.08M | 2.37M | 1.68M |
Property, Plant & Equipment | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 538.87K | 408.1K | 349K |
Fixed Asset Turnover | - | - | - | - | - | - | - | - | - | 0.00x |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 0 | 274.73K | 276.12K | 260.87K | 306.95K | 295.4K | 287.23K | 277.36K | 253.71K | 173.07K |
Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 580.96K | 720.84K | 2.07M |
Other Non-Current Assets | 1.9K | 132.76K | 0 | 0 | 0 | 0 | 0 | 1.68M | 986.51K | 1.16M |
Total Assets | 1.64M▲ 0% | 2.28M▲ 39.7% | 444.66K▼ 80.5% | 522.33K▲ 17.5% | 72.54M▲ 13787.9% | 54.6M▼ 24.7% | 36.28M▼ 33.6% | 8.15M▼ 77.5% | 29.77M▲ 265.1% | 27.07M▲ 0% |
Asset Turnover | - | - | - | - | - | - | - | - | - | 0.00x |
Asset Growth % | 95.78% | 39.66% | -80.54% | 17.47% | 13787.95% | -24.73% | -33.56% | -77.53% | 265.14% | 414.02% |
Total Current Liabilities | 885.9K | 1.34M | 1.13M | 3.96M | 695.86K | 1.21M | 2.41M | 10.36M | 5.47M | 3.59M |
Accounts Payable | 0 | 0 | 0 | 0 | 267.59K | 594.14K | 1.5M | 9.95M | 4.51M | 0 |
Days Payables Outstanding | - | - | - | - | 6.27K | 14.32K | 35.27K | 44K | 11.14K | 8.65K |
Short-Term Debt | 0 | 1.12M | 322.53K | 249.8K | 0 | 0 | 0 | 0 | 0 | 0 |
Deferred Revenue (Current) | 506.91K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 379K | 219.28K | 810.79K | 3.71M | 0 | 0 | 0 | 0 | 954.58K | 3.59M |
Current Ratio | 1.84x | 1.40x | 0.15x | 0.07x | 103.81x | 45.00x | 14.96x | 0.49x | 5.01x | 7.07x |
Quick Ratio | 1.84x | 1.40x | 0.15x | 0.07x | 103.81x | 45.00x | 14.96x | 0.49x | 5.01x | 7.07x |
Cash Conversion Cycle | - | - | - | - | - | - | - | - | - | - |
Total Non-Current Liabilities | 0 | 0 | 0 | 155.94K | 37.26M | 40.15M | 38.92M | 1.52M | 464.27K | 71.85K |
Long-Term Debt | 0 | 0 | 0 | 0 | 32.48K | 0 | 0 | 0 | 0 | 0 |
Capital Lease Obligations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | -35.63K | 37.23M | 40.15M | 38.92M | 1.52M | 464.27K | 71.85K |
Total Liabilities | 885.9K | 1.34M | 1.13M | 4.12M | 37.96M | 41.36M | 41.32M | 11.88M | 5.93M | 3.66M |
Total Debt | 0 | 1.12M | 322.53K | 249.8K | 32.48K | 0 | 0 | 0 | 0 | 0 |
Net Debt | -1.01M | 400.4K | 165.49K | 228.55K | -71.54M | -52.63M | -28.38M | -1.2M | -14.43M | -6.88M |
Debt / Equity | - | 1.19x | - | - | 0.00x | - | - | - | - | 0.00x |
Debt / EBITDA | - | - | - | - | - | - | - | - | - | -0.00x |
Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | 0.22x |
Interest Coverage | - | -264.81x | -183.88x | -133.64x | -171.32x | -27667.98x | - | - | -735.69x | - |
Total Equity | 750.23K▲ 0% | 945.02K▲ 26.0% | -688.66K▼ 172.9% | -3.6M▼ 422.4% | 34.58M▲ 1061.3% | 13.25M▼ 61.7% | -5.04M▼ 138.1% | -3.73M▲ 26.1% | 23.83M▲ 739.4% | 22.76M▲ 0% |
Equity Growth % | -4.68% | 25.96% | -172.87% | -422.38% | 1061.33% | -61.7% | -138.08% | 26.11% | 739.42% | 1389.66% |
Book Value per Share | 33.13 | 33.14 | -17.82 | -75.59 | 114.78 | 12.82 | -4.84 | -3.40 | 12.65 | 3.14 |
Total Shareholders' Equity | 750.23K | 945.02K | -688.66K | -3.6M | 34.58M | 13.25M | -5.04M | -3.31M | 24.58M | 23.41M |
Common Stock | 5.3M | 7.84M | 11.11M | 12.26M | 68.45M | 84.12M | 92.94M | 100.18M | 139.88M | 0 |
Retained Earnings | -6.68M | -9.74M | -14.75M | -18.17M | -36.42M | -77.4M | -107.71M | -118.61M | -153.65M | -134.34M |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | -57.91K | -80.98K | -101.18K | -138.68K | -173.32K | -177.86K | -185.22K | -192.52K | 38.36M | -138.68K |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -419.97K | -751.79K | -649.1K |
BCTX Cash Flow Statement
BriaCell Therapeutics Corp. (BCTX) cash flow — operating, investing & free cash flow history
| Metric | Jul'17 | Jul'18 | Jul'19 | Jul'20 | Jul'21 | Jul'22 | Jul'23 | Jul'24 | Jul'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | -1.91M | -4.95M | -5.12M | -1.55M | -9.89M | -15.87M | -31.89M | -32.97M | -39.07M | -33.9M |
Operating CF Margin % | - | - | - | - | - | - | - | - | - | - |
Operating CF Growth % | -21.12% | -159.16% | -3.34% | 69.63% | -535.98% | -60.55% | -100.9% | -3.38% | -18.52% | -44.21% |
Net Income | -3.22M | -5.41M | -5.82M | -4.94M | -17.63M | -34.13M | -27.27M | -6.55M | -36.5M | -37.06M |
Depreciation & Amortization | 290 | 16.88K | 18.83K | 18.73K | 19.46K | 19.42K | 20.51K | 114.64K | 147.89K | 122.75K |
Stock-Based Compensation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1.01M |
Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Cash Items | 271.74K | 903.45K | -361.74K | 88.77K | 10.63M | 18.73M | 99.73K | -36.17M | -80.47K | -1.73M |
Working Capital Changes | 1.03M | -466.68K | 1.04M | 3.28M | -2.91M | -497.54K | -4.74M | 9.64M | -2.65M | 572.51K |
Change in Receivables | -3.49K | -11.98K | 15.59K | -24.19K | 12.68K | -14.66K | 7.02K | -1M | 1.02M | -2.06K |
Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Payables | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -5.39M | -1.11M |
Cash from Investing | 149.85K | -590.5K | 1.35M | 0 | 0 | 0 | 0 | -931.67K | -10.61M | -19.05M |
Capital Expenditures | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -624.21K | 0 | 0 |
CapEx % of Revenue | - | - | - | - | - | - | - | - | - | - |
Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 6.99M |
Cash from Financing | 2.89M | 5.29M | 3.01M | 1.44M | 82.92M | -4.76M | 5.31M | 6.04M | 63.04M | 46.56M |
Debt Issued (Net) | 0 | 1.14M | 0 | 27.59K | -421.52K | 0 | 0 | 0 | 0 | 0 |
Equity Issued (Net) | 2.89M | 4.15M | 3.01M | 1.41M | 83.34M | -4.73M | 5.31M | 6.04M | 63.04M | 57.41M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 | -12.93M | -63.52K | 0 | 0 | 0 |
Other Financing | 0 | 0 | 0 | 0 | 0 | -29.98K | 0 | 0 | 0 | -10.86M |
Net Change in Cash | 1.1M▲ 0% | -377.65K▼ 134.4% | -757.22K▼ 100.5% | -170.63K▲ 77.5% | 71.55M▲ 42031.2% | -20.77M▼ 129.0% | -26.25M▼ 26.4% | -28.23M▼ 7.5% | 13.24M▲ 146.9% | -9.65M▲ 0% |
Free Cash Flow | -1.91M▲ 0% | -4.95M▼ 159.2% | -5.12M▼ 3.3% | -1.55M▲ 69.6% | -9.89M▼ 536.0% | -15.87M▼ 60.5% | -31.89M▼ 100.9% | -33.59M▼ 5.3% | -39.07M▼ 16.3% | -33.9M▲ 0% |
FCF Margin % | - | - | - | - | - | - | - | - | - | - |
FCF Growth % | -21.12% | -159.16% | -3.34% | 69.63% | -535.98% | -60.55% | -100.9% | -5.33% | -16.32% | 1.52% |
FCF per Share | -84.41 | -173.70 | -132.48 | -32.67 | -32.82 | -15.37 | -30.63 | -30.62 | -20.74 | -4.68 |
FCF Conversion (FCF/Net Income) | 0.59x | 0.92x | 0.88x | 0.31x | 0.57x | 0.46x | 1.18x | 6.88x | 1.07x | 0.91x |
Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
BCTX Key Ratios
BriaCell Therapeutics Corp. (BCTX) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | -418.57% | -637.98% | -4538.83% | - | -111.45% | -143.93% | -661.16% | - | -363.02% | -172.45% |
Return on Invested Capital (ROIC) | -1232.55% | -689.81% | -1140.62% | - | - | - | - | - | -1263.16% | -290.44% |
Debt / Equity | - | 1.19x | - | - | 0.00x | - | - | - | - | 0.00x |
Interest Coverage | - | -264.81x | -183.88x | -133.64x | -171.32x | -27667.98x | - | - | -735.69x | - |
FCF Conversion | 0.59x | 0.92x | 0.88x | 0.31x | 0.57x | 0.46x | 1.18x | 6.88x | 1.07x | 0.91x |
Related:BCTX Dividend History·BCTX Revenue History·BCTX Price History·BCTX P/E History·BCTX Financial Ratios·BCTX Institutional Holders
BCTX SEC Filings & Documents
BriaCell Therapeutics Corp. (BCTX) SEC filings — annual & quarterly reports (10-K, 10-Q)
BCTX Frequently Asked Questions
BriaCell Therapeutics Corp. (BCTX) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
BriaCell Therapeutics Corp. (BCTX) grew revenue by 0.0% over the past year. Growth has been modest.
BriaCell Therapeutics Corp. (BCTX) reported a net loss of $37.1M for fiscal year 2025.
Dividend & Returns
BriaCell Therapeutics Corp. (BCTX) has a return on equity (ROE) of -363.0%. Negative ROE indicates the company is unprofitable.
BriaCell Therapeutics Corp. (BCTX) had negative free cash flow of $33.9M in fiscal year 2025, likely due to heavy capital investments.